Funding profile · Healthcare AI data infrastructure
BioStack Platforms
A pre-seed data infrastructure company with one investment on the public record: a $250,000 SAFE held by Robinhood Ventures Fund II. No Form D has been filed under the company’s own name.
$250KSAFE held by Robinhood Ventures Fund II, dated Jun 2, 2026
$0Total raised under BioStack’s own SEC filings, none found
10Team size, company-reported
Data as of September 25, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Oct 2025 | Company founded | Not disclosed | Sanat Mishra, Parth Patwa | Company-stated |
| By 2026 | Y Combinator | Not disclosed | Y Combinator, Spring 2026 batch | YC data |
| Jun 2, 2026 | SAFE, allocation to a venture fund | $250,000 | Robinhood Ventures Fund II | SEC filing |
What the filings show
Robinhood Ventures Fund II · Form 424B1 · filed Aug 13, 2026
- Holding
- BioStack Platforms, Inc., 680 2nd Street, San Francisco, California 94107
- Instrument
- SAFE, acquired Jun 2, 2026
- Cost
- $250,000
- Fair value
- $250,000 (carried at cost)
- Business description in filing
- “Real-world training environments for healthcare AI”
- Filing
- SEC EDGAR, CIK 0002131040
Robinhood Ventures Fund II · Form N-2 · filed Jun 30, 2026
- Holding
- BioStack Platforms, Inc.
- Instrument
- SAFE, acquired Jun 2, 2026
- Cost
- $250,000
- Fair value
- $250,000 (carried at cost)
- Business description in filing
- “Data sets for training models in healthcare and drug discovery”
- Filing
- SEC EDGAR, CIK 0002131040
Reading the filings
- This is a fund’s disclosure, not the company’s own filing.Robinhood Ventures Fund II is a registered closed end fund that buys stakes in a broad list of startups and reports them in its own SEC filings. Its $250,000 SAFE in BioStack, filed alongside dozens of similarly sized allocations to other companies, is the only SEC document that names BioStack Platforms as of September 25, 2026.
- Same dollar figure, two different descriptions of the business.The June 30, 2026 N-2 calls BioStack a maker of “data sets for training models in healthcare and drug discovery.” The August 13, 2026 424B1, filed about six weeks later, calls it “real-world training environments for healthcare AI.” The dollar amount, $250,000 at cost and at fair value, does not change between the two filings. The wording shift lines up with the pivot BioStack describes in its own Y Combinator launch post, from selling data sets toward selling simulation environments.
- No Form D under BioStack’s own name.A search of SEC EDGAR company records and full text search for “BioStack Platforms” and “getbiostack” turns up no CIK for the company and no Form D. Companies raising only through SAFEs sold to a small number of funds, or relying on exemptions other than Regulation D, are not required to make a Form D filing, so this gap does not by itself mean no other money has moved.
- The fair value has not moved.Both filings carry the SAFE at cost, $250,000 equals $250,000, which is standard for a recent, unpriced instrument and does not indicate any markup or markdown by Robinhood Ventures Fund II.
- Team size is a company figure, not a filing figure.The 10 person team size on the Y Combinator company page is self-reported and not corroborated by any SEC or other public filing found.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Accelerator | Y Combinator, Spring 2026 batch. Primary partner listed as Nicolas Dessaigne. | YC data |
| Institutional capital | $250,000 SAFE held by Robinhood Ventures Fund II, a retail focused venture fund, dated Jun 2, 2026. | Public record |
| Customers | Company says it has grown to “17 customers and prospects, including top AI labs.” None named. | Company-stated |
| Hiring | Open roles for RL and machine learning engineers listed on the Y Combinator jobs page, salary ranges $120K to $350K plus equity. | Company-stated |
| Third party read | An independent YC batch review found “zero evidence of product traction, customers, or revenue” as of its assessment, alongside credible founder research backgrounds. | Independent |
What to watch
- A Form D or other SEC filing under BioStack Platforms’ own name, which would show a priced round or a broader SAFE raise beyond the Robinhood Ventures Fund II allocation.
- Whether Robinhood Ventures Fund II marks the BioStack SAFE up or down in a future filing.
- Named customers or disclosed revenue.
- Any additional venture fund disclosures naming BioStack as a portfolio holding.
The BioStack Platforms story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- Public recordRobinhood Ventures Fund II, Form 424B1, schedule of investments
- Public recordRobinhood Ventures Fund II, Form N-2, schedule of investments
- Public recordSEC EDGAR company search and full text search, “biostack”
- IndependentBioStack Platforms review
- CompanyBioStack Platforms: Real world training envs for healthcare AI models
- CompanyLaunch YC: BioStack Platforms, Realistic healthcare simulation environments
Compiled from SEC and other public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in BioStack Platforms. This page is not an offer to sell or a recommendation to buy any security.